Press Releases

September 4, 2024
Parexel Strengthens Real World Research Offering
Read more
September 4, 2024
Parexel Strengthens Real World Research Offering
Mike D’Ambrosio appointed as Senior Vice President, Global Head, Real World Research, reflecting the company’s commitment to an evidence-based approach in ensuring safety and efficacy in drug development efforts for customers worldwide.
Read More
August 12, 2024
Parexel’s Near-Term Greenhouse Gas Reduction Targets Validated by Science Based Target Initiative (SBTi)
Parexel announced that its near-term science-based greenhouse gas reduction (GHG) targets have been validated by the Science Based Targets initiative (SBTi). SBTi validation is a recognition that is widely considered the gold standard for setting and reducing corporate GHG emissions.
Read More
July 29, 2024
Parexel Releases 2023 Environmental, Social and Governance Report
Parexel's ESG Report is part of its annual commitment to disclose and communicate the progress of its sustainability priorities, underscoring the company’s core values of putting Patients First and delivering With Heart™.
Read More
April 25, 2024
Parexel and Palantir Expand Collaboration to Accelerate Clinical Data Delivery and Power Clinical Outcomes for Patients
Parexel and Palantir announced a multi-year strategic partnership to leverage artificial intelligence to help enhance and accelerate the delivery of safe and effective clinical trials for the world’s biopharmaceutical customers.
Read More
April 4, 2024
Parexel Named “Best Contract Research Organization” at 17th Annual Vaccine Industry Excellence (ViE) Awards
Company recognized by a distinguished industry advisory board for its expertise and leadership in supporting the development of vaccines
Read More
March 18, 2024
Parexel Announces CEO Succession Plan
Chief Operating & Growth Officer Peyton Howell to succeed Jamie Macdonald effective May 15, 2024; Mr. Macdonald to retire as CEO and continue on the Board of Directors through Dec. 31, 2024
Read More
February 1, 2024
Parexel Appoints Susan R. Salka to Board of Directors
Ms. Salka brings more than 30 years of healthcare leadership and staffing expertise, including strong C-suite, financial and ESG expertise to advance the company’s Patients-first focus and growth initiatives.
Read More
January 10, 2024
Parexel and Japanese Foundation for Cancer Research Announce Strategic Alliance
Collaboration streamlines patient access to oncology clinical trials further expands Parexel's Site Alliance Network across Asia/Pacific
Read More